138 related articles for article (PubMed ID: 30091015)
1. A novel human mAb (MERS-GD27) provides prophylactic and postexposure efficacy in MERS-CoV susceptible mice.
Niu P; Zhao G; Deng Y; Sun S; Wang W; Zhou Y; Tan W
Sci China Life Sci; 2018 Oct; 61(10):1280-1282. PubMed ID: 30091015
[No Abstract] [Full Text] [Related]
2. Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient.
Niu P; Zhang S; Zhou P; Huang B; Deng Y; Qin K; Wang P; Wang W; Wang X; Zhou J; Zhang L; Tan W
J Infect Dis; 2018 Sep; 218(8):1249-1260. PubMed ID: 29846635
[TBL] [Abstract][Full Text] [Related]
3. Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection.
Qiu H; Sun S; Xiao H; Feng J; Guo Y; Tai W; Wang Y; Du L; Zhao G; Zhou Y
Antiviral Res; 2016 Aug; 132():141-8. PubMed ID: 27312105
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus.
Choi JH; Woo HM; Lee TY; Lee SY; Shim SM; Park WJ; Yang JS; Kim JA; Yun MR; Kim DW; Kim SS; Zhang Y; Shi W; Wang L; Graham BS; Mascola JR; Wang N; McLellan JS; Lee JY; Lee H
PLoS One; 2020; 15(5):e0232757. PubMed ID: 32384116
[TBL] [Abstract][Full Text] [Related]
5. A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein.
Chen Y; Lu S; Jia H; Deng Y; Zhou J; Huang B; Yu Y; Lan J; Wang W; Lou Y; Qin K; Tan W
Emerg Microbes Infect; 2017 May; 6(5):e37. PubMed ID: 28536429
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus.
Corti D; Zhao J; Pedotti M; Simonelli L; Agnihothram S; Fett C; Fernandez-Rodriguez B; Foglierini M; Agatic G; Vanzetta F; Gopal R; Langrish CJ; Barrett NA; Sallusto F; Baric RS; Varani L; Zambon M; Perlman S; Lanzavecchia A
Proc Natl Acad Sci U S A; 2015 Aug; 112(33):10473-8. PubMed ID: 26216974
[TBL] [Abstract][Full Text] [Related]
7. Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections.
Ying T; Li H; Lu L; Dimitrov DS; Jiang S
Microbes Infect; 2015 Feb; 17(2):142-8. PubMed ID: 25456101
[TBL] [Abstract][Full Text] [Related]
8. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
[TBL] [Abstract][Full Text] [Related]
9. Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection.
Agrawal AS; Ying T; Tao X; Garron T; Algaissi A; Wang Y; Wang L; Peng BH; Jiang S; Dimitrov DS; Tseng CT
Sci Rep; 2016 Aug; 6():31629. PubMed ID: 27538452
[TBL] [Abstract][Full Text] [Related]
10. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein.
Widjaja I; Wang C; van Haperen R; Gutiérrez-Álvarez J; van Dieren B; Okba NMA; Raj VS; Li W; Fernandez-Delgado R; Grosveld F; van Kuppeveld FJM; Haagmans BL; Enjuanes L; Drabek D; Bosch BJ
Emerg Microbes Infect; 2019; 8(1):516-530. PubMed ID: 30938227
[TBL] [Abstract][Full Text] [Related]
11. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
Malczyk AH; Kupke A; Prüfer S; Scheuplein VA; Hutzler S; Kreuz D; Beissert T; Bauer S; Hubich-Rau S; Tondera C; Eldin HS; Schmidt J; Vergara-Alert J; Süzer Y; Seifried J; Hanschmann KM; Kalinke U; Herold S; Sahin U; Cichutek K; Waibler Z; Eickmann M; Becker S; Mühlebach MD
J Virol; 2015 Nov; 89(22):11654-67. PubMed ID: 26355094
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection.
Han HJ; Liu JW; Yu H; Yu XJ
Viruses; 2018 Nov; 10(12):. PubMed ID: 30513619
[TBL] [Abstract][Full Text] [Related]
13. Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice.
Kato H; Takayama-Ito M; Iizuka-Shiota I; Fukushi S; Posadas-Herrera G; Horiya M; Satoh M; Yoshikawa T; Yamada S; Harada S; Fujii H; Shibamura M; Inagaki T; Morimoto K; Saijo M; Lim CK
PLoS One; 2019; 14(10):e0223684. PubMed ID: 31589656
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing the MERS coronavirus threat.
Haagmans BL; Osterhaus AD
Sci Transl Med; 2014 May; 6(235):235fs19. PubMed ID: 24807556
[TBL] [Abstract][Full Text] [Related]
16. Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset.
Chen Z; Bao L; Chen C; Zou T; Xue Y; Li F; Lv Q; Gu S; Gao X; Cui S; Wang J; Qin C; Jin Q
J Infect Dis; 2017 Jun; 215(12):1807-1815. PubMed ID: 28472421
[TBL] [Abstract][Full Text] [Related]
17. Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy.
Tang XC; Marasco WA
Immunotherapy; 2015; 7(6):591-4. PubMed ID: 26098703
[No Abstract] [Full Text] [Related]
18. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development.
Mubarak A; Alturaiki W; Hemida MG
J Immunol Res; 2019; 2019():6491738. PubMed ID: 31089478
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of candidate vaccine approaches for MERS-CoV.
Wang L; Shi W; Joyce MG; Modjarrad K; Zhang Y; Leung K; Lees CR; Zhou T; Yassine HM; Kanekiyo M; Yang ZY; Chen X; Becker MM; Freeman M; Vogel L; Johnson JC; Olinger G; Todd JP; Bagci U; Solomon J; Mollura DJ; Hensley L; Jahrling P; Denison MR; Rao SS; Subbarao K; Kwong PD; Mascola JR; Kong WP; Graham BS
Nat Commun; 2015 Jul; 6():7712. PubMed ID: 26218507
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
Al-Amri SS; Abbas AT; Siddiq LA; Alghamdi A; Sanki MA; Al-Muhanna MK; Alhabbab RY; Azhar EI; Li X; Hashem AM
Sci Rep; 2017 Mar; 7():44875. PubMed ID: 28332568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
